Zevra Therapeutics (NASDAQ:ZVRA) Sets New 12-Month High – Here’s Why

Zevra Therapeutics, Inc. (NASDAQ:ZVRA)’s share price reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $9.57 and last traded at $9.37, with a volume of 237018 shares changing hands. The stock had previously closed at $9.13.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Maxim Group lifted their price objective on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. William Blair upgraded shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Roth Mkm raised their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a research report on Wednesday. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Zevra Therapeutics currently has an average rating of “Buy” and a consensus target price of $21.00.

Zevra Therapeutics Stock Performance

The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a market cap of $511.61 million, a price-to-earnings ratio of -4.87 and a beta of 1.93. The stock’s fifty day moving average is $8.19 and its 200-day moving average is $6.63.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $5.04 million. During the same period in the prior year, the business earned ($0.40) earnings per share. On average, analysts forecast that Zevra Therapeutics, Inc. will post -1.96 EPS for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Large investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in shares of Zevra Therapeutics in the 3rd quarter valued at approximately $127,000. Barclays PLC lifted its stake in Zevra Therapeutics by 292.6% in the third quarter. Barclays PLC now owns 57,599 shares of the company’s stock valued at $399,000 after buying an additional 42,926 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Zevra Therapeutics by 14.2% in the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock valued at $7,246,000 after buying an additional 129,600 shares during the period. XTX Topco Ltd bought a new stake in shares of Zevra Therapeutics during the third quarter worth $94,000. Finally, State Street Corp raised its holdings in shares of Zevra Therapeutics by 7.4% during the third quarter. State Street Corp now owns 772,825 shares of the company’s stock worth $5,363,000 after acquiring an additional 52,966 shares during the period. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.